Syndromic testing

Preparing for an uncertain respiratory season

Meet the challenges that this respiratory season will bring

It looks like we could be in for another tumultuous respiratory season. 

The Australian 2022–2023 respiratory season, which often mirrors our own in the northern hemisphere (1), began early this year with a record number of flu cases (2). And we continue to see circulation of out-of-season respiratory viruses in North America (3–8), as well as spikes in COVID-19. 

It’s hard to say what will come next, but we’re ready to help you prepare for the unexpected. Our multiplex panel tests can help you get quick, definitive answers when you need them.  

Read on to learn more about this fast and effective diagnostic approach. 

QIAstat-Dx, woman, physician, child, woman, mother, mom, asian, pharmacist, infectious disease, syndromic testing

Tackle antimicrobial resistance

Antimicrobial resistance (AMR) threatens the efficacy of our antimicrobials and increases the risk of common respiratory infections progressing to sepsis. Lower respiratory infections associated with AMR resulted in 1.5 million deaths in 2019 (9). But you can fight back against AMR. By rapidly and accurately diagnosing respiratory infections early, you can support evidence-based antimicrobial use. Join us this World Antimicrobial Awareness Week to help spread awareness and take control in the fight against AMR.
LEARN MORE

Multiplex panels can make your job easier

As cases of influenza-like illness spike this respiratory season, you and your team will be under enormous pressure. Take the stress out of diagnostics and get patients back to their families sooner with a diagnostic tool that tests for multiple circulating respiratory pathogens at once. Learn how multiplex PCR panels can save you time, improve patient outcomes and benefit your hospital as a whole. 
LEARN HOW
PHC, personalized healthcare, doctor, scientist, oncologist, pathologist, clinical, laboratory, discussing patient care, (Person/s, Scientist/s, Photography, MDx, Doctor/Physician, Personalized health care (PHC), Hospital)
Allison Glass, lab, testing

Outrunning viruses – multiplex testing in the field

Clinical virologist, Dr. Allison Glass, thrives on fast-paced results, whether she’s running an ultramarathon or running a state-of-the-art molecular diagnostics lab. Learn how she leverages the fast results provided by multiplex panel tests to stay one step ahead of viruses.
READ HER STORY

Get respiratory testing resources

The answer to your respiratory testing needs

The symptoms of flu, COVID-19 and other respiratory infections are all very similar, making them difficult to diagnose. Sensitive multiplex PCR panel testing is a fast and simple way to accurately diagnose your patients when multiple respiratory pathogens are circulating. In fact, the CDC and The Academy of Medical Sciences “strongly support multiplex testing” in this situation (10, 11).

With the QIAstat-Dx Respiratory SARS-CoV-2 Panel, you don’t just get results for 21 respiratory pathogens in about an hour. You also get access to Ct values and amplification curves, powerful connectivity features and on-demand epidemiology reports.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel
* Enterovirus and Rhinovirus are both detected, but not differentiated, with the QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Learn more about the QIAstat-Dx Respiratory SARS-CoV-2 Panel

QIAstat-Dx is your answer to rapid, comprehensive respiratory testing. With QIAstat-Dx, you get results for 21 common respiratory viruses and bacteria, including SARS-CoV-2, influenza and RSV, all in about an hour. Learn how the QIAstat-Dx Respiratory SARS-CoV-2 Panel can change the way you diagnose patients this respiratory season and beyond.

Download the flyer
Get in touch – we’re ready to help you
Our team of experts is ready to help you bring the reliability of QIAstat-Dx multiplex panel testing to your lab. Contact us to see how. 
CONTACT AN EXPERT

Additional resources

References
  1. Zhang, Y., Yakob, L., Bonsall, M.B., Hu, W. (2019) Predicting seasonal influenza epidemics using cross-hemisphere influenza surveillance data and local internet query data. Scientific Reports 9, 3262. 
  2. The Guardian. Australia’s monthly flu cases more than doubled previous record in May. https://www.theguardian.com/australia-news/2022/jun/12/australias-monthly-flu-cases-more-than-doubled-previous-record-in-may 
  3. Weekly U.S. Influenza Surveillance Report | CDC. https://www.cdc.gov/flu/weekly/index.htm 
  4. CDC COVID Data Tracker: Daily and Total Trends. https://covid.cdc.gov/covid-data-tracker/#trends_dailycases 
  5. Respiratory Adenovirus National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/adeno/natl-trend.html 
  6. Human Metapneumovirus National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/hmpv/natl-trend.html 
  7. Human Parainfluenza National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/human-paraflu/natl-trend.html 
  8. RSV National Trends - NREVSS | CDC. https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html 
  9. Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 10325: 629–655
  10. Academy of Medical Sciences (2021) COVID-19: Preparing for the future – Looking ahead to winter 2021/22 and beyond. https://acmedsci.ac.uk/file-download/4747802
  11. CDC. Testing Guidance for Clinicians When SARS-CoV-2 and Influenza Viruses are Co-circulating https://www.cdc.gov/flu/professionals/diagnosis/testing-guidance-for-clinicians-hospitaized.htm
* Some features require a QIAstat-Dx Connectivity plan. Flexible plans are available to meet your lab’s needs.
The QIAstat-Dx Analyzer is intended for in vitro diagnostic use. 
The QIAstat-Dx Respiratory SARS-CoV-2 Panel is intended for in vitro diagnostic use. 
  • This product has not been FDA cleared or approved, but has been authorized for emergency use by FDA under an EUA for use by authorized laboratories; 
  • This product has been authorized only for the detection and differentiation of nucleic acid of SARS-CoV-2 from multiple respiratory viral and bacterial organisms; and 
  • This emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetics Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declarations is terminated or authorization is revoked sooner.